Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) announced on Thursday that it has acquired a synthetic royalty on US sales of Geron Corporation's (NASDAQ: GERN) RYTELO (imetelstat) for USD125m.
RYTELO is an FDA-approved treatment for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anaemia. Geron is currently enrolling a Phase 3 trial of imetelstat in myelofibrosis patients who are relapsed/refractory to JAK-inhibitors.
This acquisition increases Royalty Pharma's synthetic royalty funding for 2024 to USD925m.
Royalty Pharma will receive tiered royalty payments on RYTELO's US net sales, ranging from 7.75% of annual net sales up to USD500m, and 3.0% of annual net sales between USD500m and USD1bn, to 1.0% of annual net sales over USD1bn. Payments to Royalty Pharma will cease if the aggregate royalties payable through 30 June 2031 reach a multiple of 1.65 its investment, otherwise the royalty payments will continue until Royalty Pharma receives a multiple of 2.0 its investment.
Unicycive Therapeutics' OLC NDA accepted by FDA
AOTI announces CMS review for Topical Oxygen Therapy coverage
ANGLE plc highlights dual CTC and ctDNA analysis in NSCLC research
Johnson & Johnson seeks approval for DARZALEX FASPRO in smoldering multiple myeloma
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Royalty Pharma acquires RYTELO royalty interest from Geron
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation